<DOC>
	<DOCNO>NCT00670501</DOCNO>
	<brief_summary>The primary objective study demonstrate reduction proportion new vertebral fracture postmenopausal woman osteoporosis follow 3-years treatment 20 40 mcg/day teriparatide plus calcium vitamin D compare calcium vitamin D alone .</brief_summary>
	<brief_title>Effects Teriparatide Treatment Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Ambulatory , postmenopausal woman . A minimum either one moderate two mild atraumatic vertebral fracture , minimum seven evaluable nonfractured vertebra . Hip BMD lumbar spine BMD measurement least 1.0 standard deviation ( SD ) average bone mass young , healthy woman ( Tscore ) patient few two moderate fracture patient previously treat therapeutic dos bisphosphonates fluoride Normal clinically nonsignificant abnormal laboratory value ( serum calcium , PTH ( 184 ) , &amp; urine calcium must within normal limit baseline ; 25hydroxyvitamin D must lower limit normal &amp; 3 time upper limit normal baseline ) . Fractures area bone affect disease osteoporosis ( example , cancer Paget 's disease ) . Satisfactory baseline thoracic lumbar spinal xray view obtain determine centralized xray quality assurance center ( example , severe scoliosis kyphosis ) . Current recent ( within 1 year prior randomization ) metabolic bone disorder postmenopausal osteoporosis , Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis Current recent ( within 1 year prior randomization ) disease affect bone metabolism , hypoparathyroidism , hyperparathyroidism , hyperthyroidism . Currently suspect carcinoma history carcinoma 5 year prior randomization . Nephrolithiasis urolithiasis 2 year prior randomization . Current recent ( within 1 year prior randomization ) sprue , inflammatory bowel disease , malabsorption syndrome , indication poor intestinal absorption calcium , combination low urinary calcium excretion elevate serum intact parathyroid hormone level . Poor medical psychiatric risk treatment investigational drug , opinion investigator . Treatment androgens anabolic steroid 6 month prior randomization . Treatment calcitonins 2 month prior randomization . Treatment estrogen Treatment progestins 3 calendar month prior randomization , 2 month 12 calendar month prior randomization . Treatment corticosteroid . Treatment fluorides 6 month prior randomization 60 day 24 month prior randomization . Treatment oral bisphosphonates 3 month prior randomization 60 day 24 month prior randomization ; treatment intravenous bisphosphonates 24 month prior randomization . Treatment vitamin D &gt; 50,000 IU/week , dose calcitriol , analog , agonists 6 month prior randomization . The 25hydroxyvitamin D laboratory value randomization must lower limit normal three time upper limit normal . Treatment coumarins indandione derivative 3 month prior randomization ; treatment heparins &gt; 10,000 U/day 30 day 6 month prior randomization . Treatment calcium aluminumcontaining antacid Treatment drug know affect bone metabolism 6 month prior randomization . Treatment investigational drug month prior calcium vitamin D runin phase . Treatment investigational drug certain therapeutic class month prior calcium &amp; vitamin D runin phase .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>